This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:


peer-reviewed publication

trusted source


Inflammasome study offers hope for autoinflammatory disease treatment

Inflammasome study offers hope for autoinflammatory disease treatment
The NLRP3 PYD engineered to resemble the NLRP12 PYD has an altered ability to stimulate ASC polymerization. (A) Sequence alignment of the murine NLRP3 and NLRP12 PYD domains, with the mutated residues highlighted and the mutations shown below the sequence. (B to E) HEK293T cells stably expressing murine ASC-GFP were transiently transfected with pEF6 expression plasmids encoding Cherrytagged murine NLRP3 constructs with their PYD engineered to contain a single NLRP12 residue substitution. Credit: Science Signaling (2024). DOI: 10.1126/scisignal.abg8145

University of Queensland researchers have discovered how the "on-switch" for the body's inflammation machinery can get stuck and cause rare genetic inflammatory diseases. Professor Kate Schroder and her team at UQ's Institute for Molecular Bioscience have been studying the NLRP3 inflammasome, a protein complex that drives inflammation.

The team involved IMB researchers, including Jared Coombs and Dr. Alina Zamoshnikova. The research paper was published in Science Signaling.

"The inflammasome protects us during infection by triggering an immune response, but it can also go wrong and cause uncontrolled inflammation and disease," Professor Schroder said.

"Autoinflammatory diseases occur when your body creates an without a cue, ranging from very mild inflammation such as a rash, to life-threatening inflammatory responses leading to fever, blindness, deafness and cognitive decline.

"In those patients, there are mutations that stick the inflammasome on/off switch in the 'on' position so it is always firing, causing inflammation driven by a mutation instead of an infection or wound.

"The inflammation also can't be turned off without drug intervention."

Professor Schroder said the body's NLRP3 inflammasome is involved in neurogenerative diseases including Alzheimer's, such as arthritis, and cancer and gout.

"Our team found NLPR3 can be switched on permanently by a mutation in the protein NLRP12, with further tests revealing that NLRP12 also acts as a natural inhibitor to control NLRP3," she said.

"The two proteins are very closely related within the same family and like many siblings, one tries to control the other and stop it from doing what it wants to do."

Professor Schroder said because NLRP12 exists naturally in our cells, NLRP12 modulators may provide an effective treatment for people with autoinflammatory disease associated with overactive inflammasome NLRP3 signaling.

"There are artificial NLRP3 inhibitors currently in , developed by our research team and others," she said.

"With our discovery that NLRP12 turns off NLRP3, we aim to make further inroads to understand these diseases."

More information: Jared R. Coombs et al, NLRP12 interacts with NLRP3 to block the activation of the human NLRP3 inflammasome, Science Signaling (2024). DOI: 10.1126/scisignal.abg8145

Journal information: Science Signaling
Citation: Inflammasome study offers hope for autoinflammatory disease treatment (2024, March 19) retrieved 22 July 2024 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Researchers develop a dual NLRP1 and NLRP3 inflammasome inhibitor, a novel class of anti-inflammatory drug


Feedback to editors